Andere Sprachen Akebia Therapeutics, Inc.

Aktien

A1XF0S

US00972D1054

AKBA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
1,37 ^USD	0,00 %		-1,44 %	+10,48 %

16.04.	Akebia Therapeutics, Inc. und STA Pharmaceutical Hong Kong Limited schließen zweite Änderung der Liefervereinbarung ab	CI
28.03.	Sektor-Update: Aktien des Gesundheitswesens steigen am Donnerstag vorbörslich	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Averoa Seeks EU Approval for Chronic Kidney Disease Drug	23.04.
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	16.04.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03.04.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
Sector Update: Health Care Stocks Advance Premarket Thursday	28.03.
Sector Update: Health Care	28.03.
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	28.03.
Akebia Shares Rally Premarket After FDA Approves Vafseo	28.03.
U.S. FDA approves Akebia's anemia drug	28.03.
U.S. FDA approves Akebia's anemia drug	28.03.
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis	28.03.
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	28.03.
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	15.03.
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024	15.03.
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	14.03.
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	14.03.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	14.03.
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Akebia Therapeutics, Inc.

Aktien

A1XF0S

US00972D1054

AKBA

Andere Sprachen

Filter